28.27
Schlusskurs vom Vortag:
$30.31
Offen:
$30.31
24-Stunden-Volumen:
492.03K
Relative Volume:
0.95
Marktkapitalisierung:
$1.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-10.82%
1M Leistung:
+1.58%
6M Leistung:
+124.19%
1J Leistung:
+41.56%
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Vergleichen Sie ORKA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ORKA
Oruka Therapeutics Inc
|
28.27 | 1.47B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka Therapeutics Inc (ORKA) - GuruFocus
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyMarket Sentiment Report & Fast Exit Strategy with Risk Control - Улправда
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3%Here's What Happened - MarketBeat
Why Oruka Therapeutics Inc. stock is a must watch in 2025Recession Risk & Real-Time Chart Pattern Alerts - DonanımHaber
Piper Sandler Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. stock compares to growth peersWeekly Gains Report & AI Based Buy and Sell Signals - Улправда
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Is Oruka Therapeutics Inc. stock a dividend growth opportunityJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - Улправда
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors - TipRanks
Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors By Investing.com - Investing.com India
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors - Investing.com
Oruka Therapeutics Appoints Christopher Martin to Board - TipRanks
Oruka Therapeutics Announces New Board Member and Board Transition - The Manila Times
B Group Inc. Increases Position in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics (ORKA) Stock Analysis Report | Financials & Insights - Benzinga
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Geode Capital Management LLC - Defense World
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Affinity Asset Advisors LLC - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com Nigeria
Can Oruka Therapeutics Inc. stock deliver consistent earnings growthCEO Change & AI Based Buy and Sell Signals - Newser
Will Oruka Therapeutics Inc. stock sustain high P E ratios2025 Volatility Report & Safe Capital Growth Plans - Newser
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliable2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics stock hits 52-week high, reaching $31.01 - Investing.com
Should I hold or sell Oruka Therapeutics Inc. stock in 2025Market Movement Recap & AI Based Buy and Sell Signals - Newser
Is Oruka Therapeutics Inc. (HQ1) stock undervalued at current priceJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Will Oruka Therapeutics Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - Newser
How Oruka Therapeutics Inc. (HQ1) stock performs during market turbulence2025 Dividend Review & Breakout Confirmation Trade Signals - Newser
What valuation ratios show for Oruka Therapeutics Inc. (HQ1) stock2025 Support & Resistance & Reliable Breakout Forecasts - Newser
Will Oruka Therapeutics Inc. (HQ1) stock hit analyst forecastsWeekly Profit Analysis & Breakout Confirmation Alerts - Newser
Franklin Resources Inc. Purchases 292,421 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Sale |
28.52 |
13,000 |
370,795 |
205,084 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):